Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details related to dividend reinvestment.
- Share Price: 1381 pence per Ordinary Share; $44.288 per ADS.
- Transaction Date: January 10, 2013 (Notification date); January 3, 2013 (Dividend payment date).
Material Changes
The filing details increases in shareholdings for three individuals resulting from the reinvestment of dividends paid on January 3, 2013. These transactions include both personal contributions and company matching contributions under the Deferred Annual Bonus Plan.
- Mrs D P Connelly: Acquired 27.164 ADSs (personal) and 27.820 ADSs (company match).
- Mr M Dunoyer: Acquired 39.000 Ordinary Shares (personal) and 39.670 Ordinary Shares (company match).
- Mr W C Louv: Acquired 28.873 ADSs (personal) and 29.500 ADSs (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that notional dividends accrued under the matching element will be paid out based on vesting percentages following a three-year measurement period for 2010 and 2011 bonuses.
Investor Verification Points
- Verify the vesting schedule and conditions for the 2010 and 2011 deferred bonus awards mentioned.
- Confirm the total number of shares held by the named directors post-transaction.
- Review the full terms of the GlaxoSmithKline 2009 Deferred Annual Bonus Plan to understand the matching contribution mechanics.